1. Academic Validation
  2. Role of Tilianin against Acute Lung Injury in In Vitro LPS-Induced Alveolar Macrophage Cells and an In Vivo C57BL/6 Mice Model

Role of Tilianin against Acute Lung Injury in In Vitro LPS-Induced Alveolar Macrophage Cells and an In Vivo C57BL/6 Mice Model

  • J Environ Pathol Toxicol Oncol. 2020;39(4):335-344. doi: 10.1615/JEnvironPatholToxicolOncol.2020035136.
Yonghong Zhang 1 Zhenshuai Fu 2
Affiliations

Affiliations

  • 1 Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710004, China.
  • 2 Department of ICU, Sunshine Union Hospital, Weifang City, Shandong Province, 261000, China.
Abstract

Acute lung injury (ALI) is a disorder of pulmonary tissue caused by prolonged inflammation and uncontrolled oxidative stress. Tilianin is a natural polyphenol, acknowledged for its anti-inflammatory and antioxidant activities. The goal of this work was to explore the effect of tilianin in an LPS-challenged ALI model. The mechanistic investigation was carried out using both in vitro and in vivo experiments. The RAW264.7 macrophage cell and C57BL/6 mice were treated with Tilianin (10 and 20 μM) and then induced with LPS (1 μg/mL) overnight. The C57BL/6 mouse was administered LPS intratracheally (2 mg/kg) to induce ALI prior to tilianin intraperitoneal treatment (10 mg/kg). In vitro, the results showed that Tilianin reduced secretion of LPS-induced proinflammatory cytokine. In vivo, prophylactic treatment with tilianin attenuated infiltration of macrophages and histopathological changes and improved inflammation as shown by a marked reduction in inflammatory mediators found in bronchoalveolar lavage fluid (BALF). Furthermore, tilianin effectively suppressed MDA levels and GSH and SOD in ALI were increased. Collectively, these findings suggest that tilianin is a potential agent for ameliorating LPS-induced ALI.

Figures
Products